Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06094491

Virtual Diabetes Group Visits Across Health Systems

The purpose of this project is to evaluate the effectiveness of a virtual diabetes group visits on patients with type 2 diabetes mellitus (T2DM).

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

About this study

Managing diabetes can be complex and burdensome; patients must modify their diet, take medications, check their blood sugar, and visit their healthcare providers regularly. Diabetes group visits (GVs)-virtual group education and diabetes support, including goal setting-create a unique setting where patients can connect with peers and receive medical care and support. GVs can improve glycemic control and decrease healthcare utilization. GVs can provide patients with comprehensive care for their multimorbid chronic condition.

Virtual GVs provide an opportunity to adapt to the current trends of telehealth and the ability to increase reach and scalability across multiple sites. Before the model can be widely adopted, important questions about the effectiveness and implementation of the virtual diabetes GV model need to be addressed. The investigators propose to build on an established program of diabetes GVs. This proposal aims to implement the virtual GV model (VIDA: Virtual Diabetes Group Visits Across Health Systems) in two distinct health systems in the Chicago region. Access Community Health Network (ACCESS) is one of the largest federally qualified health centers (FQHCs) in the United States with 35 sites across the Chicago metropolitan area, providing care for 175,000 medically under-resourced and low-income patients each year. Advocate Health Care (ADVOCATE) is a large, integrated private not-for-profit health system that includes 26 hospitals and more than 500 ambulatory sites. The system provides care across more than 129 primary care clinics in Illinois serving over 117,000 patients. Both are community-based health systems serving low-income communities in Chicago and are network partners of the Chicago Chronic Conditions Engagement Network (C3EN).

No studies have systematically implemented virtual diabetes GVs for adults with T2DM in the real-world primary care setting or across distinct health systems. The ability to train, implement, and evaluate virtual GVs across systems with different care models provides the opportunity to learn about adaptation and the obstacles and facilitators for implementation. This proposed study will compare virtual diabetes GVs to usual care using a type I hybrid effectiveness-implementation design via a pragmatic cluster randomized trial.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient at a PARTICIPATING clinic (at least one visit in year prior to first GV)
  • Type 2 diabetes
  • ≥ 18 years old
  • A1C>8% within 6 months prior to first GV (we will first recruit patients with A1C>9%, then if spaces still available A1C>8.5%, then if spaces still available A1C>8%)
  • At least one additional cardiovascular condition (hypertension, heart disease, stroke, hyperlipidemia, peripheral vascular disease, or BMI ≥ 30)
  • English or Spanish speaking
  • PCP assented to recruiting patient
  • Patient provides written consent

Treatment and study plan

Virtual Group Visit

Behavioral

Group visits must have these core components: diabetes education, group social support and goal setting.

Primary outcomes

  1. A1c

    Time frame: 12 months

    This is blood test that measures the percent of glucose and hemoglobin bound together.

Secondary outcomes

  1. Systolic blood pressure

    Time frame: 12 months

    Systolic blood pressure measures the arterial pressure

  2. Body Mass Index

    Time frame: 12 months

    Measure of body fat based on height and weight

  3. Low density lipoproteins

    Time frame: 12 months

    a measure of cholesterol in the blood

Sponsors and collaborators

Lead sponsor

University of Chicago

Other

Collaborators

  • ACCESS Community Health Network
  • Midwest Clinicians' Network
  • National Institute on Minority Health and Health Disparities (NIMHD)
  • Wake Forest University Health Sciences

Registry information

Official study title

VIDA: Virtual Diabetes Group Visits Across Health Systems: Randomized Control Trial

Acronym: VIDA

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Oct 23, 2023
Registry last updated
Jul 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.